Orphan drug for Parkinson’s patients slated for 3Q NDA filing, Chelsea says
Drug development company Chelsea Therapeutics plans to file a new drug application in the third quarter for its lead drug candidate, an orphan drug for Parkinson’s disease patients. Charlotte, North Carolina-based Chelsea (NASDAQ:CHTP) reaffirmed the plans following correspondence with the U.S. Food and Drug Administration regarding data from a recent study on its drug candidate […]